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Summary
AIMS OF THE STUDY: While studies show that antibiotic
treatment for uncomplicated diverticulitis seems to have
no benefit, most experts advocate antimicrobial therapy
for complicated diverticulitis. However, even for uncom-
plicated diverticulitis, most clinicians are very reluctant to
withhold antibiotics. Biomarkers could help to guide antibi-
otic therapy as this approach has been shown to be effec-
tive for acute respiratory infections. In this diagnostic co-
hort study we evaluated whether procalcitonin could be a
biomarker to distinguish complicated from uncomplicated
cases of diverticulitis.
METHODS: Complicated diverticulitis was defined as hav-
ing abscess formation or perforation diagnosed by abdom-
inal computed tomography (CT) scan. In all patients with
suspected diverticulitis, procalcitonin values were mea-
sured at admission and on day 2. These values were
blinded for clinicians, and treatment was carried out ac-
cording to the physician’s judgement. Two groups (com-
plicated vs uncomplicated diverticulitis) were defined. Pa-
tients who had received antibiotic treatment before admis-
sion were excluded. Difference in procalcitonin values was
calculated for both groups using the Mann-Whitney test.
Receiver operating characteristics (ROC) were calculated
to determine cut-off values for procalcitonin according to
the gold standard (abdominal CT scans).
RESULTS: 115 patients were included for analysis. 35 pa-
tients (30%) suffered from complicated diverticulitis. The
median procalcitonin value for uncomplicated diverticulitis
was significantly lower compared to complicated divertic-
ulitis (median 0.05, interquartile range [IQR] 0.05–0.06 ng/
l vs median 0.13, IQR 0.05–0.23 ng/l; p <0.0001). In the
ROC analysis, the sensitivity and specificity were 81% and
91% when the highest procalcitonin value (days 1 and 2)
was considered, with a cut-off value of 0.1 ng/l.
CONCLUSION: Procalcitonin was able to differentiate with
a high sensitivity and specificity between complicated and
uncomplicated cases of diverticulitis when combined with
abdominal CT scans. As most clinicians still treat uncom-
plicated diverticulitis with antibiotics, procalcitonin could
be an interesting parameter for guiding therapy and de-
creasing antibiotic usage. This should be further evaluated
in randomised trials.
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Introduction
Although there is growing evidence to promote the avoid-
ance of antibiotic therapy in uncomplicated diverticulitis
[1, 2], physicians often continue to prescribe antibiotics in
any case of diverticulitis. Availability of biomarkers would
be useful to differentiate between complicated and uncom-
plicated diverticulitis and thereby guide antibiotic therapy.
Complicated diverticulitis is usually defined as Hinchey
>Ib [3].
Procalcitonin has been identified as a biomarker in the di-
agnosis of bacterial infections in the setting of acute respi-
ratory infections [4] and has been implemented in guide-
lines for antibiotic therapy in respective cases [4]. For
abdominal infections, the data on reliable biomarkers are
rather scarce. For appendicitis, procalcitonin failed to im-
prove diagnosis and its sensitivity was even lower than
C-reactive protein (CRP) [5]. However, procalcitonin was
able to identify more complicated cases of appendicitis [5].
In sepsis in general, procalcitonin may be helpful early in
the course of this heterogeneous disease to differentiate be-
tween bacterial infection and, e.g., post-operative inflam-
mation [6]. However the role of procalcitonin in sepsis re-
mains controversial and its trend (persistently high values
vs faster clearing kinetics) rather than isolated values seem
to have a higher clinical relevance [7].
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Available reports on biomarkers in diverticulitis have been
reviewed recently [8]. Mainly CRP has been evaluated in
small cohort studies, which show only moderate sensitivity
and specificity, and cannot be used as a single parameter.
Recent data indicate a role for foetal calprotectin or ma-
trix metalloproteinase in detecting diverticular disease, but
it has not yet been clarified whether these parameters are
useful for differentiation between complicated and uncom-
plicated courses of disease [8]. The role of procalcitonin
has not been assessed so far.
The aim of the present prospective observational study
was to evaluate if procalcitonin could differentiate between
complicated and uncomplicated cases of diverticulitis
compared to the gold-standard abdominal computed to-
mography (CT) scan. The aim was that results would guide
further prospective trials for the more restrictive use of
antibiotic therapy in cases of uncomplicated diverticulitis
with appropriate procalcitonin cut-off levels.
Material and methods
We conducted a prospective diagnostic cohort study in
two level-three emergency rooms and surgical wards in
Switzerland (Kantonsspital Olten, Switzerland, and Bürg-
erspital Solothurn, Switzerland). The study was approved
by the local ethics committee (north-western Switzerland,
Licence no.: EKNZ 2015-135) in accordance with the
Helsinki Declaration and the Swiss law for clinical studies.
All patients gave written informed consent to a physician
not involved in the study. Patients were enrolled into the
study from September 2015 to December 2016.
Inclusion criteria were: suspected diverticulitis according
to the treating physician (e.g., lower left abdominal pain,
fever, referral from a general practitioner due to suspected
diverticulitis), age >18 years, abdominal CT scan (request-
ed by a physician responsible for patient care but indepen-
dent of the study).
Exclusion criteria were severe immunodeficiency (on-go-
ing chemotherapy; corticosteroid prescription >50 mg/d
and >14 days; acute malignant haematological disease, hu-
man immunodeficiency virus [HIV] stage C3), inflamma-
tory bowel disease.
Blood was drawn by nurses on admission to the emergency
room and in the course of routine blood sampling the fol-
lowing day on the ward. Procalcitonin was determined in
addition to routine blood parameters (blood count, elec-
trolytes, creatinine, blood urea nitrogen, liver enzymes, C-
reactive protein). At the time of admission, two pairs of
blood cultures were collected. Physicians were blinded for
procalcitonin values, as it is not the current standard of care
to assess procalcitonin in cases of suspected abdominal in-
fection.
CT scans of the abdomen were ordered according to the
decision of the physician in charge and reviewed by spe-
cialist radiologists. CT scans of the abdomen were avail-
able 24 hours a day, 7 days a week and were reviewed on
site or online (at night). Radiologists were blinded to the
procalcitonin value. According to the radiology report, pa-
tients were scored as uncomplicated diverticulitis (Hinchey
Score 0–Ia) or complicated diverticulitis (with abscess for-
mation, perforation, peritonitis; Hinchey Score Ib–IV).
Patient data, including clinical parameters as well as pre-
hospital treatment, were obtained retrospectively from the
patient chart.
Procalcitonin was measured with a one-step sandwich im-
munoassay with fluorescent detection (Vidas® BRAHMS
PCTTM). The lowest detection threshold was 0.05 ng/l.
Statistics
Patient data from complicated or uncomplicated divertic-
ulitis were compared using the non-parametric Wilcoxon
matched-pairs signed rank test for laboratory parameters at
day 1 (admission) and day 2. Parameters between groups
were compared using a Mann-Whitney test. Due to the dy-
namic kinetics of procalcitonin [9], the highest values of
either day 1 (admission) or day 2 were compared. A p-val-
ue of 0.05 was considered significant. In case of multiple
testing, p-values were corrected following the Bonferroni
method. Receiver operating characteristics were calculated
to determine cut-off values for procalcitonin according to
the gold standard (abdominal CT scans). Prism 6 (Graph-
Pad Software Inc, La Jolla, CA, USA) was used to calcu-
late the statistics and draw the figures that appear in this
paper. ROC curves of paired data were compared accord-
ing to DeLong’s Method using R.
Results
From 167 recruited patients, 32 (19%) were excluded due
to already established antibiotic therapy in the outpatient
setting, 17 (10%) patients had no confirmation of diverti-
culitis and 3 (2%) had missing procalcitonin values at ad-
mission to the emergency room. Finally, 115 patients were
included for analysis (fig. 1). 35 (30%) suffered from com-
plicated diverticulitis. These patients had a longer duration
of intravenous antibiotic treatment as well as a longer du-
ration of hospitalisation (table 1). Even in uncomplicated
cases, almost all patients received antibiotic therapy (de-
tails of antibiotic therapy are shown in table 1). Only one
out of 19 blood cultures drawn on admission to the emer-
gency room from complicated cases revealed a positive
culture result (Escherichia coli and Streptococcus angi-
nosus).
Procalcitonin at admission (day 1) was significantly higher
in patients with complicated diverticulitis compared to pa-
tients with uncomplicated diverticulitis (median 0.13, in-
terquartile range [IQR] 0.05–0.23 ng/l vs median 0.05,
IQR 0.05–0.06; p <0.0001). If the highest procalcitonin
values of day 1 or day 2 were compared between the
two groups, a significant difference was observed (median
0.21, IQR 0.12–0.75 ng/l vs median 0.05, IQR 0.05–0.07;
p <0.0001). CRP and leucocyte count of complicated and
uncomplicated diverticulitis were not significantly differ-
ent at time of admission (table 2).
Compared to the gold standard (abdominal CT scan), ROC
curves of procalcitonin show moderate sensitivity (80%)
and high specificity (91%) at a cut-off point of 0.1 ng/l
when the highest value was considered (measured at ad-
mission or day 2) (area under the curve [AUC] 0.867;
confidence interval [CI] 0.791–0.942). The procalcitonin
(AUC 0.742; CI 0.633–0.852) as well as the CRP value
(AUC 0.635; CI 0.509–0.761) at admission showed only
moderate sensitivity and specificity (fig. 2). The ROC
curve and AUC for highest procalcitonin was not signifi-
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cantly different compared to the AUC of highest CRP (p =
0.144; AUC for highest CRP 0.782; CI 0.682–0.881).
Discussion
Diverticulitis is a frequent diagnosis, with about 75 hospi-
tal admissions per 100,000 persons per year, and has a low
mortality rate of less than 1% [10]. The true incidence may
be even higher, as many cases are treated outside hospitals
by family physicians.
Although it is generally believed that diverticulitis results
from microperforation of the diverticulum, some authors
have hypothesised that diverticulitis is a form of inflamma-
tory bowel disease [11]. The indication for antibiotic treat-
ment has therefore been a challenge for many years [12].
Specific biomarkers for abdominal infections are missing.
Mainly CRP and calprotectin have been assessed for di-
verticulitis but with only moderate specificity and sensitiv-
ity [8]. No reports on procalcitonin and diverticulitis are
currently available. However, procalcitonin has been eval-
uated in cases of appendicitis where it showed a strong
diagnostic value if abscess formation or perforation was
present [13]. However, procalcitonin was not useful as a
single parameter to diagnose appendicitis. In a recent pub-
lished study, the authors studied the role of procalcitonin as
a marker to guide antibiotic therapy in cases of peritonitis
after surgery [14]. Subgroup analysis revealed a trend for
shorter duration of therapy in the procalcitonin group, but
the study was underpowered due to small sample size. It is
therefore not clear whether procalcitonin is able to guide
antibiotic therapy in the case of bacterial peritonitis follow-
ing surgery.
The use of procalcitonin as a biomarker has been shown to
decrease antibiotic consumption in respiratory infections
[9]. We believe that treatment and clinical course of diver-
ticulitis have some similarities to respiratory infections.
Even if procalcitonin did not show superiority compared to
other biomarkers in abdominal infections [5], it could have
its place in the case of diverticulitis. Similar to respiratory
infections, most cases of diverticulitis are of non-bacteri-
al origin [15], but in complicated diverticulitis, which of-
ten leads to peritonitis, patients may benefit from antibiotic
treatment. Similar to non-bacterial respiratory infections,
Table 1: Demographics and characterisation of antibiotic (AB) treatment of complicated and uncomplicated cases of diverticulitis.
Complicated Uncomplicated
% % p-value
Cases (n) 35 30% 80 69%
Age (years, median, range) 62 (31–87) 61 (33–90) 0.962
Gender (m/f) 16/19 46%/54% 36/44 45%/55%
Hospitalisation (days, median, range) 7 (3–45) 4 (1–17) <0.0001
Positive blood culture (1/19) (0/18)
Antibiotic therapy (n) 35 100% 78 98%
Intravenous AB therapy 35 100% 68 85%
Days of AB therapy intravenous (median, range) 6 (3–25) 4 (0–14) <0.0001
Type
Tazobactam/piperacillin 16 46% 41 51%
Ceftriaxone/metronidazole 14 40% 24 30%
Ciprofloxacin/metronidazole 3 9% 2 3%
Amoxicillin-clavulanic acid 0 0% 1 1%
Meropenem 1 3% 0 0%
Cefepime/metronidazole 1 3% 0 0%
Days of oral AB therapy (median, range) 7 (0–15) 7 (3–13) 0.391
Type
Amoxicillin-clavulanic acid 16 46% 55 69%
Ciprofloxacin/metronidazole 11 31% 20 25%
Amoxicillin 1 3% 0 0%
Amoxicillin-clavulanic acid/metronidazole 0 0% 3 4%
Cefuroxime/metronidazole 1 3% 0 0%
Levofloxacin/metronidazole 1 3% 0 0%
Cotrimoxazole 1 3% 0 0%
None 4 11% 0 0%
Table 2: Procalcitonin, C-reactive protein and leucocyte count on admission (day 1) and day 2.
Uncomplicated Complicated
Admission Day 2 Admission Day 2
p-value













PCT (ng/l) 0.05 0.05–0.06 0.05 0.05–0.06 0.13 0.05–0.23 0.16 0.12–0.63 0.712 0.022 <0.0001 <0.0001
CRP (mg/l) 79 45–113 94 55–121 123 53–201 149 115–239 0.05 0.004 0.022 <0.0001
leucocytes (G/
l)
11.4 9.1–14.2 8.4 6.5–11.0 12.6 10.4–14.9 10.4 8.3–13.3 <0.0001 0.004 0.292 0.002
CRP = C-reactive protein; PCT = procalcitonin Data are shown as median and interquartile range (IQR). Differences between groups (e.g., complicated vs uncomplicated) were
compared using the unpaired Mann-Whitney test. Differences between admission (day 1) and day 2 within each group of either complicated or uncomplicated diverticulitis were
compared using the paired Wilcoxon matched-pairs test. According to the Bonferroni method, a p-value of 0.0125 was considered significant after four multiple tests.
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most clinicians might be very reluctant to omit antibiot-
ic treatment for uncomplicated diverticulitis to avoid and
prevent complications due to a possible bacterial infection.
This was the case in our present study, where most patients
with uncomplicated diverticulitis were treated with antibi-
otics.
Our results indicate that procalcitonin may be useful to
differentiate uncomplicated from complicated diverticuli-
tis when compared to the gold standard of abdominal CT
scans. Procalcitonin values had a tendency to higher sensi-
tivity and specificity compared to CRP in discerning com-
Figure 1: Included and excluded patients. All recruited patients
gave written informed consent. Patients were excluded for analysis
if the CT scan did not confirm suspected clinical diagnosis of diver-
ticulitis, if procalcitonin was not determined at admission, or if pa-
tients had already received antibiotic treatment in the outpatient
setting before admission to the emergency room.
plicated from uncomplicated diverticulitis, but their AUC
were not significantly different, probably due to the small
sample size. In 9% of the patients with complicated diver-
ticulitis, procalcitonin values were below 0.1 ng/l, which
therefore makes this method of analysis unsuitable as a re-
placement for CT scans. In addition, the procalcitonin val-
ue on admission had only moderate sensitivity and speci-
ficity, so a follow- up procalcitonin value on day 2 seems
to be necessary. This may be due to the dynamic kinetics
of procalcitonin [9] and the delay between onset of infec-
tion and measurement of procalcitonin. In summary, we do
not conclude that measurement of procalcitonin could re-
place CT scans or that it should be used as a single parame-
ter, but in the case of uncomplicated diverticulitis, it could
have the potential to rule out antibiotic treatment. We hy-
pothesise that in the patient population of the present study,
procalcitonin-guided treatment would have decreased an-
tibiotic treatment by 80%. This is a similar percentage
compared to studies using procalcitonin in respiratory in-
fections, where a marked reduction of antibiotic consump-
tion was observed [9]. If laboratory tests support clinicians
in omitting antibiotic treatment for uncomplicated diverti-
culitis, its use would be justified in addition to radiological
imaging.
We are aware that our study is rather small. The aim was
to gain indications of whether procalcitonin is able to dif-
ferentiate between complicated and uncomplicated diver-
ticulitis. Our results show that procalcitonin in addition to
CT could support clinicians’ decisions on whether antibi-
otic treatment is necessary.
Further studies need to be done to answer this question in
order to reduce antibiotic treatment in uncomplicated di-
verticulitis. These studies should be performed as multi-
centre studies using larger sample sizes to obtain strong ev-
Figure 2: ROC (receiver operating characteristic) curve of procalcitonin against the gold standard of abdominal CT scan. The highest procalci-
tonin serum concentration of day 1 (admission) or day 2 showed a sensitivity of 80% and a specificity of 91%. AUC is indicated with 95% con-
fidence interval in brackets.
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idence for the use of procalcitonin in guidance of antibiotic
therapy in diverticulitis.
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